68ga-rm26
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2022 (NCT06147362)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06412952 | Early Phase 1 (Phase 1) | Oct 1, 2022 | Chinese Academy of Medical Sciences |
| NCT05549024 | Early Phase 1 (Phase 1) | Aug 16, 2022 | Chinese Academy of Medical Sciences |
| NCT06147362 | Phase 1 | Jun 1, 2022 | Karolinska Institute, Stockholm South General Hospital, Uppsala University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Stockholm South General Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1